Catalyst Pharmaceuticals Hits 52-Week Low at $19.05 Amid Market Volatility

Catalyst Pharmaceuticals, Inc. has reached a significant milestone by touching a new 52-week low of USD 19.05 on September 25, 2025. This marks a notable decline for the small-cap company, which operates within the Pharmaceuticals & Biotechnology industry.
Despite this recent downturn, Catalyst Pharmaceuticals has demonstrated a solid one-year performance of 22.39%, outperforming the S&P 500, which recorded a gain of 15.79% during the same period. The company's market capitalization stands at USD 2,458 million, reflecting its position as a small-cap player in the market.

Financial metrics indicate a price-to-earnings (P/E) ratio of 17.00, suggesting a competitive valuation relative to its earnings. Additionally, the company maintains a return on equity of 23.64%, highlighting its efficiency in generating profits from shareholders' equity. Catalyst Pharmaceuticals also has a price-to-book ratio of 2.87, providing insight into its valuation relative to its net assets.

As the stock navigates this new low, it remains a part of the Reliable Performers category on MarketsMOJO since November 2024, indicating a consistent performance track record.